ONDANSETRON ODT- ondansetron tablet, orally disintegrating The maximum mean (95% upper confidence bound) difference in QTcF from placebo after baseline correction was 19
A significant exposure Ondansetron is a medicine used to prevent nausea and vomiting caused by surgery or cancer treatments
4 or 8mg of Zofran ODT is metabolized to < 0
AUC from a 16 mg tablet was 24% greater than predicted from an 8 mg Ondansetron may impair your thinking or reactions
Common Zofran side effects may include: diarrhea or constipation; headache; drowsiness; or
AUC from a 16-mg tablet was 24% greater than predicted from an 8-mg tablet dose
According to Ph
sweating
Bottles of 30 NDC 65862-390-30 Bottles of 10,000 NDC 65862-390-19 3 x 10 Unit-dose Tablets NDC 65862-390-10
This may reflect some reduction of first-pass metabolism at higher oral doses
This copyrighted material has been downloaded from a licensed data provider
Do not swallow the tablet whole
A headache, hypoxia, and fever are some of the more commonly reported side effects
For prevention of nausea and vomiting after surgery: Adults—16 milligrams (mg) one hour before anesthesia is given
Mean bioavailability in healthy subjects, following administration of a single 8-mg tablet, is approximately 56%
This restriction requires that specific clinical criteria be met prior to Zofran ODT
The maximum mean (95% upper confidence bound) difference in QTcF from placebo after baseline correction was 19
The recommended dosage regimens for adult and pediatric patients are described in Table 1 and Table 2, respectively
CYP2D6 genetic deficiency) results in little change in overall rates of ondansetron elimination
Zofran ODT Orally Disintegrating Tablets are white, round tablets
The active ingredient in ZOFRAN ODT Orally Disintegrating Tablets is ondansetron base, the racemic form of ondansetron, and a selective blocking agent of the serotonin 5-HT3 receptor type
Ondansetron AN ODT is available as orally disintegrating tablets containing 4 mg and 8 mg ondansetron
Ondansetron is absorbed from the gastrointestinal tract and undergoes some first‑pass metabolism
Mean bioavailability in healthy subjects, following administration of a single 8-mg tablet, was recorded as being approximately 56% to 60% 10,11,12
Additional copies are available from: Office Communications Division of Drug Information, WO51, Room 2201 10903 New Zofran: ondansetron (on- dan -se-tron) , Ondissolve ODF (trade name), Zofran (trade name), Zofran ODT (trade name), Zuplenz (trade name) Classification Therapeutic: antiemetics Pharmacologic: five ht3 antagonists Pregnancy Category: B Indications Prevention of nausea and vomiting associated with highly or moderately emetogenic chemotherapy
Generic Zofran Availability
Ondansetron systemic exposure does not increase proportionately to dose
This gives the medication enough high levels of serotonin in the body--agitation, hallucinations, fever, fast heart rate, overactive reflexes, nausea, vomiting, diarrhea, loss of coordination, fainting
This multiplicity of metabolic enzymes capable of metabolising ondansetron means that inhibition or loss of one enzyme (e
Drug savings; Telehealth; Health information; Gold membership; Search
AUC from a 16-mg tablet was 24% greater than predicted from an 8-mg tablet dose
Nausea/Vomiting, Postoperative
See more Generic Name (S): ondansetron Uses This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (
It Ondansetron Dissolving Tablets What is this medication? ONDANSETRON (on DAN se tron) prevents nausea and vomiting from chemotherapy, radiation, or surgery
Ondansetron is used to prevent nausea and vomiting that is caused by cancer medicines (chemotherapy) or radiation therapy
ZOFRAN is a 5-HT3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin
ZOFRAN is also indicated for the prevention of postoperative nausea and/or vomiting
Zofran® (ondansetron) is a medication that prevents nausea and vomiting caused by chemotherapy, radiation or surgery
To reduce the risk
Common Zofran side effects may include: diarrhea or constipation; headache; drowsiness; or
ZOFRAN oral solution, 4 mg/5 mL, is a clear, colorless to light yellow liquid with a characteristic strawberry The active ingredient in ondansetron orally disintegrating tablets is ondansetron base, Mean bioavailability in healthy subjects, following administration of a single 8 mg tablet, is approximately 56%
Ondansetron side effects
View side-by-side comparisons of medication uses, ratings, cost, side effects and interactions
Then, this apparatus oscillated 31 cycles per minute in a 900 mL water bath at 37°C
puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
Zofran ODT: 4 mg [DSC], 8 mg [DSC] [contains aspartame, methylparaben sodium, propylparaben sodium; strawberry flavor] Generic: 4 mg, 8 mg
Oral ondansetron comes as a tablet, an orally disintegrating tablet (ODT), and an oral solution
Ondansetron systemic exposure does not increase Zofran and Zofran ODT are the brand-name medications that ondansetron oral tablet is based on
AUC from a 16 mg tablet was 24% greater than predicted from an 8 mg tablet dose
It can be given orally (by mouth), intramuscularly (injection into a muscle), or intravenously (injection into a vein)
This restriction requires that specific clinical criteria be met prior to To take the orally disintegrating tablet (Zofran ODT): Keep the tablet in its blister pack until you are ready to take it
Ondansetron is one of the medications most commonly used for the empiric treatment of nausea and vomiting
Zofran may be used for the treatment and prevention of nausea and vomiting caused by cancer chemotherapy, radiation, or surgery
Then, the dose is 8 mg every 8 hours
nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2
Ondansetron works in the stomach to block the signals to the brain that cause nausea and vomiting